Skip to content
HowShorted

UroGen Pharma Ltd. short interest in 2023

In 2023, UroGen Pharma Ltd.'s disclosed short interest ran from 2.47% of shares outstanding on 13 Jan 2023 to 11.49% on 29 Dec 2023, a change of +9.02 percentage points. The year's high was 11.49% on 29 Dec 2023 and its low 2.47% on 13 Jan 2023, averaging 4.97% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.43 days on 29 Dec 2023. Full history: UroGen Pharma Ltd..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for UroGen Pharma Ltd. in 2023

2023 in figures

Start of year
2.47% (13 Jan 2023)
End of year
11.49% (29 Dec 2023)
Change
+9.02 pp
High
11.49% (29 Dec 2023)
Low
2.47% (13 Jan 2023)
Average
4.97%
Highest days to cover
13.43 (29 Dec 2023)
SEC filings marked
8

Every report in 2023

UroGen Pharma Ltd. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20232.47%4.94
31 Jan 20232.47%4.56
15 Feb 20232.50%6.23
28 Feb 20232.57%5.79
15 Mar 20232.71%8.61
31 Mar 20232.73%3.96results (8-K), 10-K filed
14 Apr 20233.17%6.61
28 Apr 20233.12%3.12
15 May 20234.03%2.5210-Q filed, results (8-K)
31 May 20233.64%7.23
15 Jun 20232.80%4.75
30 Jun 20233.88%2.01
14 Jul 20234.32%4.98
31 Jul 20236.70%1.00
15 Aug 20235.49%2.4310-Q filed, results (8-K)
31 Aug 20234.65%2.93
15 Sep 20234.27%6.65
29 Sep 20234.73%8.30
13 Oct 20235.43%7.78
31 Oct 20237.56%8.15
15 Nov 20239.16%10.6410-Q filed, results (8-K)
30 Nov 20239.45%10.53
15 Dec 20239.95%9.38
29 Dec 202311.49%13.43

See also: UroGen Pharma Ltd.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.